Iclusig may find use in other cancers and '113 is better than the market believes.
Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.
Instead of selling stock whenever the wind blows, biotech execs should be buying.
The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.
How best to invest in the next important clinical trial catalyst facing Celgene.